HomeClinical TopicsFDA approves first therapy for high-risk neuroblastoma

FDA approves first therapy for high-risk neuroblastoma

On March 10, the U.S. Food and Drug Administration (FDA) approved Unituxin (dinutuximab) as part of first-line therapy for pediatric patients with high-risk neuroblastoma. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...